SG11202001050PA - Antibodies that bind egfr and cmet - Google Patents
Antibodies that bind egfr and cmetInfo
- Publication number
- SG11202001050PA SG11202001050PA SG11202001050PA SG11202001050PA SG11202001050PA SG 11202001050P A SG11202001050P A SG 11202001050PA SG 11202001050P A SG11202001050P A SG 11202001050PA SG 11202001050P A SG11202001050P A SG 11202001050PA SG 11202001050P A SG11202001050P A SG 11202001050PA
- Authority
- SG
- Singapore
- Prior art keywords
- cmet
- antibodies
- bind egfr
- egfr
- bind
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17185572 | 2017-08-09 | ||
PCT/NL2018/050537 WO2019031965A1 (en) | 2017-08-09 | 2018-08-09 | Antibodies that bind egfr and cmet |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202001050PA true SG11202001050PA (en) | 2020-03-30 |
Family
ID=59579503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202001050PA SG11202001050PA (en) | 2017-08-09 | 2018-08-09 | Antibodies that bind egfr and cmet |
Country Status (15)
Country | Link |
---|---|
US (2) | US11773170B2 (en) |
EP (1) | EP3665198A1 (en) |
JP (2) | JP2020530028A (en) |
KR (1) | KR20200042485A (en) |
AU (2) | AU2018312816B2 (en) |
BR (1) | BR112020002695A2 (en) |
CA (1) | CA3072404A1 (en) |
EA (1) | EA202090215A1 (en) |
IL (1) | IL272461A (en) |
MA (1) | MA49846A (en) |
MX (1) | MX2020001432A (en) |
PH (1) | PH12020550055A1 (en) |
SG (1) | SG11202001050PA (en) |
TW (1) | TW201910354A (en) |
WO (1) | WO2019031965A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108602888B (en) | 2015-10-23 | 2022-10-04 | 美勒斯公司 | Binding molecules that inhibit cancer growth |
TWI782930B (en) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof |
AU2018246873B2 (en) | 2017-03-31 | 2021-05-06 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene |
AU2019243665B2 (en) * | 2018-03-30 | 2023-06-01 | Merus N.V. | Multivalent antibody |
US11254736B2 (en) * | 2019-02-15 | 2022-02-22 | Integral Molecular, Inc. | Antibodies comprising a common light chain and uses thereof |
CN114702587A (en) | 2019-05-09 | 2022-07-05 | 美勒斯公司 | Variant domains and their isolation for multimerizing proteins |
AU2020349462A1 (en) | 2019-09-16 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging |
CN112898427B (en) * | 2019-12-03 | 2023-06-30 | 同济大学苏州研究院 | anti-c-Met single-arm antibody and preparation method and application thereof |
EP4372001A1 (en) | 2021-07-14 | 2024-05-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereof |
WO2023172133A1 (en) | 2022-03-07 | 2023-09-14 | Merus N.V. | Combination therapy including antibodies that bind egfr and cmet |
WO2023172134A1 (en) | 2022-03-07 | 2023-09-14 | Merus N.V. | Treatment with an antibody that binds egfr and cmet. |
WO2024002235A1 (en) * | 2022-06-29 | 2024-01-04 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-egfr/met antibodies and uses thereof |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
FI884924A (en) | 1987-10-28 | 1989-04-29 | Oncogen | HUMANIMMUGLOBULIN SOM PRODUCERATS MED HYBRID-DNA-TEKNIK. |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
JP3502093B2 (en) | 1991-07-15 | 2004-03-02 | ザ・ウエルカム・ファウンデーション・リミテッド | Production of antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
DE29706518U1 (en) | 1997-04-11 | 1997-05-22 | E. Missel GmbH & Co., 70374 Stuttgart | Carrier system for bathtubs, shower trays or whirlpools |
ES2246069T3 (en) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | PROCEDURE FOR THE PREPARATION OF MULTI-SPECIFIC ANTIBODIES THAT HAVE COMMON AND MULTIMERIC COMPONENTS. |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
SI1533380T1 (en) | 1999-04-15 | 2010-03-31 | Crucell Holland Bv | Recombinant protein production in a human cell comprising at least one E1 protein of adenovirus |
DE29915950U1 (en) | 1999-09-10 | 1999-12-30 | Cmw Automation Gmbh | Device for filling the cells of an accumulator with electrolyte |
US20070111201A1 (en) | 2001-04-30 | 2007-05-17 | Benjamin Doranz | Reverse transfection of cell arrays for structural and functional analyses of proteins |
BRPI0210771B8 (en) | 2001-07-04 | 2021-05-25 | Chromagenics Bv | construction of recombinant DNA, method for producing a gene product in a cell, and, use of a DNA sequence |
US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
US20050130224A1 (en) | 2002-05-31 | 2005-06-16 | Celestar Lexico- Sciences, Inc. | Interaction predicting device |
CA2872136C (en) | 2002-07-18 | 2017-06-20 | Merus B.V. | Recombinant production of mixtures of antibodies |
CA2512647C (en) | 2003-01-07 | 2013-10-08 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
CA2526284C (en) | 2003-06-25 | 2014-11-18 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
US8124085B2 (en) | 2004-05-05 | 2012-02-28 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
MXPA06014075A (en) | 2004-06-03 | 2007-03-15 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof. |
AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
CN101163501A (en) | 2005-02-23 | 2008-04-16 | 梅里麦克制药股份有限公司 | Bispecific binding agents for modulating biological activity |
US20060212956A1 (en) | 2005-03-14 | 2006-09-21 | Genentech, Inc. | Animal model of ligand activated HER2 expressing tumors |
TWI671403B (en) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | Method for controlling controlled assembly of polypeptide |
PT1999154E (en) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
US8290739B2 (en) | 2006-10-20 | 2012-10-16 | Amfit, Inc. | Method for determining relative mobility of regions of an object |
CA2670315A1 (en) | 2006-11-21 | 2008-11-20 | The Regents Of The University Of California | Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof |
EP3248617A3 (en) | 2007-02-16 | 2018-02-21 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
MX2009010611A (en) | 2007-04-03 | 2010-03-26 | Micromet Ag | Cross-species-specific bispecific binders. |
US7705103B2 (en) | 2007-06-22 | 2010-04-27 | 3M Innovative Properties Company | Polydiorganosiloxane polyoxamide copolymers |
US8158757B2 (en) | 2007-07-02 | 2012-04-17 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for treating and diagnosing cancer |
WO2009051974A1 (en) | 2007-10-17 | 2009-04-23 | Nuvelo, Inc. | Antibodes to cll-1 |
WO2009086197A1 (en) | 2007-12-20 | 2009-07-09 | Monogram Biosciences, Inc. | Her-2 diagnostic methods |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
SI2235064T1 (en) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
JP5530367B2 (en) | 2008-02-05 | 2014-06-25 | ザイムワークス,インコーポレイテッド | Method for determining correlated residues in proteins or other biopolymers using molecular dynamics |
AU2009263082C1 (en) | 2008-06-27 | 2018-11-01 | Merus N.V. | Antibody producing non-human mammals |
KR101706255B1 (en) | 2008-08-29 | 2017-02-14 | 심포젠 에이/에스 | Recombinant anti-epidermal growth factor receptor antibody compositions |
JP5677972B2 (en) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | Human serum albumin linker and its conjugates |
ES2535723T3 (en) | 2009-01-15 | 2015-05-14 | Laboratory Corporation Of America Holdings | Methods for determining the patient's response by measuring Her-3 |
JP2012515540A (en) | 2009-01-26 | 2012-07-12 | ゲンマブ エー/エス | Methods for producing antibody mixtures |
TWI461211B (en) | 2009-03-20 | 2014-11-21 | Genentech Inc | Anti-her antibodies |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
CN102471378B (en) | 2009-06-26 | 2014-04-02 | 瑞泽恩制药公司 | Readily isolated bispecific antibodies with native immuneoglobulin format |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
KR20120059568A (en) | 2009-08-21 | 2012-06-08 | 메리맥 파마슈티컬즈, 인크. | Antibodies against the ectodomain of erbb3 and uses thereof |
WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
JP5960598B2 (en) | 2009-11-04 | 2016-08-02 | アフィボディ・アーベー | HER3 binding polypeptide |
SI3095871T1 (en) | 2010-02-08 | 2019-06-28 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
ES2537207T3 (en) | 2010-08-16 | 2015-06-03 | Novimmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
PT2606070T (en) | 2010-08-20 | 2017-03-31 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
TW201302793A (en) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | Novel antigen binding proteins |
US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
CN103429620B (en) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | There is the antibody design of the stable heterodimeric of mutation in Fc domains |
WO2012116317A2 (en) | 2011-02-24 | 2012-08-30 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
MX2013010379A (en) | 2011-03-11 | 2014-03-27 | Merrimack Pharmaceuticals Inc | Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers. |
BR112013022887A2 (en) | 2011-03-15 | 2016-12-06 | Merrimack Pharmaceuticals Inc | overcoming resistance to erbb pathway inhibitors |
SG10201602371VA (en) | 2011-03-25 | 2016-04-28 | Glenmark Pharmaceuticals Sa | Hetero-dimeric immunoglobulins |
GB201106395D0 (en) | 2011-04-14 | 2011-06-01 | Hubrecht Inst | Compounds |
DK2707391T3 (en) | 2011-05-13 | 2018-02-05 | Gamamabs Pharma | ANTIBODIES AGAINST HER3 |
JPWO2012176779A1 (en) | 2011-06-20 | 2015-02-23 | 協和発酵キリン株式会社 | Anti-erbB3 antibody |
CN106167526A (en) | 2011-07-15 | 2016-11-30 | 昂考梅德药品有限公司 | RSPO bonding agent and its application |
US9567827B2 (en) | 2013-07-15 | 2017-02-14 | Downhole Technology, Llc | Downhole tool and method of use |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
EP2760893B1 (en) | 2011-09-30 | 2018-09-12 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
RU2620068C2 (en) | 2011-11-23 | 2017-05-22 | МЕДИММЬЮН, ЭлЭлСи | Binding molecule specific for her3, and their applications |
BR112014013495A8 (en) | 2011-12-05 | 2017-06-13 | Novartis Ag | antibodies to epidermal growth factor receptor 3 (her3) targeting her3 domain iii and domain iv |
KR102083957B1 (en) | 2011-12-05 | 2020-03-04 | 노파르티스 아게 | Antibodies for epidermal growth factor receptor 3 (her3) |
CN102448183A (en) | 2012-01-18 | 2012-05-09 | 大唐移动通信设备有限公司 | Uu interface reconfiguration method and equipment |
JP6231503B2 (en) | 2012-03-09 | 2017-11-15 | プロメガ コーポレイションPromega Corporation | pH sensor |
US20130259867A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
AR090549A1 (en) | 2012-03-30 | 2014-11-19 | Genentech Inc | ANTI-LGR5 AND IMMUNOCATE PLAYERS |
ES2743399T3 (en) | 2012-04-20 | 2020-02-19 | Merus Nv | Methods and means for the production of Ig-like heterodimeric molecules |
TW201843172A (en) * | 2012-06-25 | 2018-12-16 | 美商再生元醫藥公司 | Anti-egfr antibodies and uses thereof |
EP3470431A1 (en) | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
WO2014060365A1 (en) | 2012-10-15 | 2014-04-24 | Universität Zürich Prorektorat Mnw | Bispecific her2 ligands for cancer therapy |
LT3447069T (en) * | 2012-11-21 | 2020-12-10 | Janssen Biotech, Inc. | Bispecific egfr/c-met antibodies |
JP2016510411A (en) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Methods and monitoring of treatment with WNT pathway inhibitors |
WO2014159580A1 (en) | 2013-03-14 | 2014-10-02 | Oncomed Pharmaceuticals, Inc. | Met-binding agents and uses thereof |
CA2908515A1 (en) | 2013-04-05 | 2014-10-09 | Laboratory Corporation Of America Holdings | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation |
WO2014182970A1 (en) | 2013-05-08 | 2014-11-13 | Zymeworks Inc. | Bispecific her2 and her3 antigen binding constructs |
WO2014197854A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use |
US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
EP3030577B1 (en) | 2013-08-07 | 2019-10-02 | Universität zu Köln | Novel nrg1 fusion genes in cancer |
US9551208B2 (en) | 2013-08-26 | 2017-01-24 | Halliburton Energy Services, Inc. | Identifying uncertainty associated with a stimulated reservoir volume (SRV) calculation |
US10519247B2 (en) | 2013-11-01 | 2019-12-31 | Board Of Regents,The University Of Texas System | Targeting HER2 and HER3 with bispecific antibodies in cancerous cells |
WO2015130172A1 (en) | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibodies that bind egfr and erbb3 |
US11279770B2 (en) | 2014-02-28 | 2022-03-22 | Merus N.V. | Antibody that binds ErbB-2 and ErbB-3 |
BR112016020752B1 (en) | 2014-03-11 | 2023-11-14 | Regeneron Pharmaceuticals, Inc | ISOLATED ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, PHARMACEUTICAL COMPOSITION, AND, USE OF A PHARMACEUTICAL COMPOSITION |
KR102352573B1 (en) | 2014-04-04 | 2022-01-18 | 바이오노믹스 인코포레이티드 | Humanized antibodies that bind lgr5 |
WO2016077734A2 (en) | 2014-11-14 | 2016-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nk cells with an increased antibody-dependent cellular toxicity (adcc) against tumors |
MA41123A (en) | 2014-12-02 | 2017-10-10 | Oncomed Pharm Inc | POLYTHERAPY FOR CANCER TREATMENT |
DK3115376T3 (en) | 2015-07-10 | 2018-11-26 | Merus Nv | HUMANT CD3 BINDING ANTIBODY |
CN108602888B (en) | 2015-10-23 | 2022-10-04 | 美勒斯公司 | Binding molecules that inhibit cancer growth |
AU2018246873B2 (en) | 2017-03-31 | 2021-05-06 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene |
-
2018
- 2018-08-09 SG SG11202001050PA patent/SG11202001050PA/en unknown
- 2018-08-09 WO PCT/NL2018/050537 patent/WO2019031965A1/en unknown
- 2018-08-09 MA MA049846A patent/MA49846A/en unknown
- 2018-08-09 EP EP18766377.8A patent/EP3665198A1/en active Pending
- 2018-08-09 KR KR1020207006947A patent/KR20200042485A/en not_active Application Discontinuation
- 2018-08-09 US US16/637,464 patent/US11773170B2/en active Active
- 2018-08-09 BR BR112020002695-6A patent/BR112020002695A2/en unknown
- 2018-08-09 AU AU2018312816A patent/AU2018312816B2/en active Active
- 2018-08-09 TW TW107127888A patent/TW201910354A/en unknown
- 2018-08-09 MX MX2020001432A patent/MX2020001432A/en unknown
- 2018-08-09 JP JP2020507522A patent/JP2020530028A/en not_active Ceased
- 2018-08-09 EA EA202090215A patent/EA202090215A1/en unknown
- 2018-08-09 CA CA3072404A patent/CA3072404A1/en active Pending
-
2020
- 2020-02-04 IL IL272461A patent/IL272461A/en unknown
- 2020-02-07 PH PH12020550055A patent/PH12020550055A1/en unknown
-
2021
- 2021-05-06 AU AU2021202874A patent/AU2021202874A1/en active Pending
-
2023
- 2023-08-09 US US18/446,795 patent/US20240174756A1/en active Pending
- 2023-12-20 JP JP2023214896A patent/JP2024029049A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL272461A (en) | 2020-03-31 |
TW201910354A (en) | 2019-03-16 |
AU2021202874A1 (en) | 2021-06-03 |
BR112020002695A2 (en) | 2020-08-25 |
CN111094351A (en) | 2020-05-01 |
EP3665198A1 (en) | 2020-06-17 |
US20240174756A1 (en) | 2024-05-30 |
KR20200042485A (en) | 2020-04-23 |
EA202090215A1 (en) | 2020-07-01 |
MA49846A (en) | 2020-06-17 |
US11773170B2 (en) | 2023-10-03 |
PH12020550055A1 (en) | 2020-10-19 |
WO2019031965A1 (en) | 2019-02-14 |
AU2018312816A1 (en) | 2020-02-27 |
MX2020001432A (en) | 2020-03-20 |
JP2024029049A (en) | 2024-03-05 |
JP2020530028A (en) | 2020-10-15 |
US20200247892A1 (en) | 2020-08-06 |
CA3072404A1 (en) | 2019-02-14 |
AU2018312816B2 (en) | 2021-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272461A (en) | Antibodies that bind egfr and cmet | |
IL272218A (en) | Anti-sirp-alpha antibodies and related methods | |
ZA202105676B (en) | Anti-trem2 antibodies and related methods | |
IL287565A (en) | Antibodies that bind cd39 and uses thereof | |
ZA201904491B (en) | Anti-tl1a/anti-tnf-alpha bispecific antigen binding proteins and uses thereof | |
HK1244219A1 (en) | Heterodimeric antibodies that bind cd3 and tumor antigens | |
ZA202105920B (en) | Antibody that binds erbb-2 and erbb-3 | |
SG11201607109QA (en) | Antibodies that bind egfr and erbb3 | |
IL252480A0 (en) | Heterodimeric antibodies that bind cd3 and tumor antigens | |
IL260846B (en) | Antigen binding proteins that bind pd-l1 | |
HK1251240A1 (en) | Tumor-specific anti-egfr antibody and application thereof | |
ZA201908072B (en) | Igf-1r monoclonal antibodies and uses thereof | |
ZA201701912B (en) | Antigen binding proteins that bind cxcr5 | |
ZA201901892B (en) | Antibodies that bind interleukin-2 and uses thereof | |
IL274121A (en) | Bispecific antibodies binding alk-1 and bmpr-2 | |
IL274502A (en) | Anti-ox40 antibodies and uses thereof | |
IL258924A (en) | Humanized anti-dkk2 antibody and uses thereof | |
GB201712032D0 (en) | Antibodies and uses thereof | |
IL274202A (en) | Anti-glyco-muc1 antibodies and their uses | |
PT3110849T (en) | Antibody that binds erbb-2 and erbb-3 |